[Form 4] Anavex Life Sciences Insider Trading Activity

Rhea-AI Filing Summary

Christopher U. Missling, President, CEO and Director of Anavex Life Sciences Corp. (AVXL), reported the vesting and acquisition of 125,000 option shares. The Form 4 shows that on 08/20/2025 Mr. Missling acquired 125,000 stock options by exercise of a previously granted option with an $8.58 exercise price. The exercised option became vested following satisfaction of a performance milestone tied to publication of preclinical blarcamesine prevention AD data.

The underlying option was part of a larger grant made on 03/31/2025 for 500,000 options that vest in four equal tranches based on performance milestones; this transaction reflects one tranche vesting. The Form 4 is signed by Mr. Missling on 08/22/2025.

Positive

• Performance milestone met leading to vesting of 125,000 options tied to publication of preclinical blarcamesine prevention AD data
• Clear disclosure of grant date (03/31/2025), exercise price ($8.58) and number of options exercised (125,000)
• Reporting person holds executive and board roles (President, CEO and Director), ensuring transaction transparency

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Insider exercised a vested tranche tied to a specific performance milestone; governance disclosure appears routine and complete.

The filing documents an exercise of 125,000 options by the company's President/CEO and Director following satisfaction of a named performance milestone. The disclosure identifies the original grant date, vesting structure (four equal performance-based tranches), the specific milestone achieved, exercise price ($8.58), and post-transaction beneficial ownership of 125,000 shares of common stock from this tranche. From a governance and disclosure perspective, the Form 4 communicates the material elements investors require for insider transactions.

Securities Analyst

TL;DR: Transaction reflects compensation realization by a senior insider after a milestone; not an earnings or revenue event.

The report details that one of four performance-based vesting tranches from a 03/31/2025 option grant vested due to published preclinical data, enabling the President/CEO to acquire 125,000 options at an $8.58 strike on 08/20/2025. This is a securities transaction and not an operational or financial result; the filing does not state the total post-transaction aggregate holdings beyond this tranche. Impact on the capital structure is not quantified in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MISSLING CHRISTOPHER U

(Last) (First) (Middle)

630 5TH AVENUE

20TH FLOOR

(Street)

NEW YORK NY 10111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.58	08/20/2025		A		125,000(1)		08/20/2025	03/31/2035	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

	/s/Christopher Missling	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Christopher Missling report on Form 4 for AVXL?

He reported acquisition via exercise of 125,000 stock options on 08/20/2025 at an exercise price of $8.58.

Why did the 125,000 options vest for AVXL insider Christopher Missling?

The options vested because a performance milestone was met: Publication of preclinical blarcamesine prevention AD data.

When was the original option grant that included the vested tranche made?

The original option grant was made on 03/31/2025 for 500,000 options that vest in four equal performance-based tranches.

What roles does the reporting person hold at Anavex Life Sciences (AVXL)?

The Form 4 lists Christopher U. Missling as a Director and as an Officer with the title President and CEO.

When was the Form 4 signed by the reporting person?

The Form 4 bears the reporting person's signature dated 08/22/2025.